What treatment would you recommend for a patient with early-stage TNBC treated per KEYNOTE-522, PD-L1 CPS >10, with metastatic recurrence within 12 months of treatment completion?

Is there a duration of time during which you would not re-challenge with immunotherapy?

Answer from: Medical Oncologist at Academic Institution

In the absence of a clinical trial option for this patient with triple-negative breast cancer (TNBC) who had completed the KEYNOTE-522 regimen <12 months ago for non-metastatic TNBC and who now has metastatic TNBC which tested PD-L1 positive (PD-L1 CPS >10), I would offer immunotherapy with pe...

Comments

Medical Oncologist at NYU Langone Medical Center
Regulatory issues aside, would pembrolizumab + sac...

Medical Oncologist at Cancer Treatmt Center of America
Although not yet approved, I would use data from t...

Medical Oncologist at NYU Winthrop Hospital
Agree with sacituzumab and pembrolizumab.

Medical Oncologist at Breastlink Medical Group
Also in favor of saci and pembro + biopsy and sequ...

Medical Oncologist at St Lukes Cancer Care Assocs
I would go straight to ADC. I won’t add CPI ...

Medical Oncologist at Millennium Physicians
Agree with the above, either use saci alone or wit...

Medical Oncologist at University of Texas MD Anderson Cancer Center
There is no information on whether the primary or ...

Please select the option that best describes you:

What treatment would you recommend for a patient with early-stage TNBC treated per KEYNOTE-522, PD-L1 CPS >10, with metastatic recurrence within 12 months of treatment completion?

Related Questions